Homeopathic Drug Product Safety, Quality, and Transparency Act

Ensuring Access to Products: The Act seeks to address the needs of consumers and practitioners for continued access to homeopathic drug products (Section 2).

Reducing Regulatory Barriers: The bill aims to prevent federal agencies from imposing regulatory barriers that could unreasonably limit access to safe products and accurate information (Section 2).

Standardized Safety and Quality: Homeopathic products would be subject to safety and quality standards found in the Homeopathic Pharmacopoeia of the United States or other accredited voluntary consensus standards (Section 4).

Clearer Labeling for Consumers: For retail sale, labels would be required to include purposes or indications for use supported by various sources, such as traditional homeopathic references or peer-reviewed medical journals (Section 4).

Expert Oversight: The establishment of a Homeopathic Drug Product Advisory Committee ensures that a group of experts, including manufacturers, practitioners, and consumers, can advise the Secretary on regulation (Section 4).

Mandatory Testing for High-Risk Materials: Manufacturers of products using starting materials that may present a substantial risk of illness or injury in undiluted form must ensure and document that the substance does not exceed a specific safe level (Section 4).

New Labeling Requirements: Products intended for retail sale must include specific statements noting that indications have not been evaluated by the Food and Drug Administration (Section 4).